-transparent.png){kind=logo}
Hybridomas producing human monoclonal antibodies (MAbs) against human cytomegalovirus (CMV) were generated by fusion of human spleen cells and mouse myeloma cells. Two of the six MAbs obtained neutralized viral infectivity even at concentrations lower than 1 microgram/ml. One MAb required complement for neutralization but the other did not. Both MAbs recognized viral proteins of Mr 130,000 and 55,000. Furthermore, these neutralizing MAbs bound to the surface membrane of CMV-infected cells. These results suggest that human MAbs may provide a new means of passive immunization against CMV infection in humans.
Related Publications
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
March 1990,
The Journal of general virology,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
September 2019,
Vaccines,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
January 1987,
Annales de medecine interne,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
March 1989,
The Journal of infectious diseases,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
November 2008,
BMC biotechnology,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
August 1985,
The Journal of infectious diseases,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
December 2022,
Microbiology spectrum,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
January 1991,
The Journal of general virology,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
October 1992,
Hybridoma,
Y Masuho, and
Y Matsumoto, and
T Sugano, and
S Fujinaga, and
Y Minamishima
January 1983,
Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie,
